Secukinumab,Adalimumab
Novartis,Abbvie
['axspa', 'adalimumab', 'secukinumab', 'ec 18']
 presents the results of surpass study &amp; reports no difference in radiographic progression between adalimumab &amp; secukinumab arms in #axspa #eular2023 (and very low progression overall) 
Researcher, rheumatologist. Charité Universitätsmedizin Berlin. @Official_ASAS Young ASAS leader 2023-2025